For patients newly diagnosed with MM, the results of this study revealed that domestic long-acting G-CSF administered on day 6 led to marked decreases in early infection and treatment delay relative to standard G-CSF, while no difference was detected between these two regimens in terms of the incidence of FN. The gene discussed is CSF3; the disease is infection.